VeonGen Therapeutics recently announced regulatory and clinical updates for VG801, an investigational dual-adeno-associated virus (AAV) subretinal gene therapy for Stargardt disease and other ABCA4-associated retinal dystrophies.
Let’s start with a refresher on VeonGen.
Headquartered in Munich, Germany, the clinical-stage genetic medicine company is focused on developing innovative therapies, and currently has two candidates in its ophthalmology pipeline:
- VG801, its lead asset (and the focus of today’s story)
- VG901, an intravitreal (IVT) AAV gene therapy for retinitis pigmentosa (RP) caused by CNGA1 mutations
Note: In June 2025, we reported the company had renamed itself (from ViGeneron GmbH) and rebranded to match its transition “from a platform innovator to a clinical-stage company.”
And what does its technology platform look like?
VeonGen has three proprietary technology platforms (vgAAV, vgRNA REVeRT [Reconstitution Via mRNA Trans-splicing], and AAV Transactivation) that address key challenges in gene therapy:
- cellular transduction
- large gene delivery beyond AAV size limits
- regulation of disease-relevant gene expression
Noted! Moving on to VG801.
This lead asset leverages VeonGen’s aforementioned proprietary gene therapy platforms to:
- combine novel vgAAV2 capsid technology for efficient photoreceptor transduction with vgRNA REVeRT large-gene delivery technology
- enable delivery and reconstitution of a full-length functional human ABCA4 gene in retinal photoreceptor cells.
The purpose of these technologies: to address the underlying genetic cause of Stargardt disease across different ABCA4 mutations, offering the potential for a genotype-agnostic therapeutic approach and functional benefit to patients.
What is its regulatory status?
VG801 has received the three following FDA designations in addition to being selected for the FDA’s Rare Disease Endpoint Advancement (RDEA) pilot program:
- Regenerative Medicine Advanced Therapy (RMAT)
- Rare Pediatric Disease (RPD)
- Orphan Drug (ODD)
The purpose of the RDEA program: to offer selected sponsors an opportunity for increased engagement with FDA experts from the Center for Drug Evaluation and Research and/or Center for Biologics Evaluation and Research to discuss novel efficacy endpoints intended to establish substantial evidence of effectiveness for a rare disease treatment.
And for good measure: VG901 has also received FDA designations, including RPD and ODD.
So has VG801 been assessed in any clinical trials?
Indeed. The ongoing first-in-human (FIH), single-arm, open-label, dose-exploration, multicenter phase 1/2 clinical trial (NCT07002398) has dosed 15 patients across three dose cohorts (low, medium, and high), including adult and pediatric patients.
The main outcome measures:
- Primary: adverse events (AEs) and serious AEs (SAEs)
- Secondary will evaluate abnormal examination results in the following:
- best corrected visual acuity (BCVA)
- optical coherence tomography (OCT)
- fundus autofluorescence (FAF)
- microperimetry
- novel virtual reality visual test (VRVT [exploratory])
- we’ll touch more on this later
Talk about the findings.
In the phase 1/2 trial VG801 demonstrated:
- consistent and sustained functional improvements through Month 12 across BCVA, VRVT, and microperimetry fixation assessments
- stable retinal structures
- a favorable safety profile to date
Among the 13 patients with measurable baseline BCVA, all demonstrated improvements from baseline to Month 6 or Month 12, with 11 (85%) achieving gains of ≥5 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters.
- Moreover: 7 (54%) of these participants achieved ≥10 ETDRS letters and 4 (31%) achieved at least ≥15 ETDRS letters.
What about these clinical and regulatory updates?
VeonGen reported it has reached alignment with the FDA at a RMAT Type B meeting on key clinical and Chemistry, Manufacturing and Controls (CMC) aspects of the VG801 pivotal phase 3 program, including:
- pivotal study design: primary endpoint; study duration; and control arm
- CMC: use of the existing clinical batch for the pivotal phase 3 study and key aspects of the commercial manufacturing strategy
The importance: these outcomes provide important regulatory clarity and support preparations for global pivotal phase 3 development.
Anything else?
Bringing back the VRVT we mentioned earlier: VeonGen is simultaneously advancing the VRVT through the aforementioned FDA’s RDEA Pilot Program to support its development as a functional vision measure in Stargardt disease.
- What’s in the works: VeonGen has conducted a dedicated VRVT validation study to support its potential use in a future pivotal trial toward a Biologics License Application (BLA) submission.
VG801 has also received phase 1/2 clinical trial authorizations in Europe and China, supporting its global development strategy.
Any comments from the company?
As VeoGen’s Caroline Man Xu, MBA, PhD, co-founder and CEO, noted: “The consistent and sustained functional improvements observed in both adult and pediatric patients reinforce our confidence in the program.”
She added: “We remain focused on advancing VG801 toward global pivotal development and ultimately delivering this innovative therapy to patients worldwide.”
Lastly: When can we expect an update?
While VeonGen did not provide a specific timeline for updates, the phase 1/2 trial has an estimated completion date of December 2027, and development for the phase 3 program is actively in the works.
As usual, stay tuned for updates!